ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Adam E. Saltman
Irvin B. Krukenkamp
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horimoto, H.
Right arrow Articles by Krukenkamp, I. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horimoto, H.
Right arrow Articles by Krukenkamp, I. B.

Ann Thorac Surg 1999;68:844-849
© 1999 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Nitric oxide–generating ß-adrenergic blocker nipradilol preserves postischemic cardiac function

Hitoshi Horimoto, MDa, Adam E. Saltman, MD, PhDa, Glenn R. Gaudette, MSca, Irvin B. Krukenkamp, MDa

a Division of Cardiothoracic Surgery, University Hospital at Stony Brook, State University of New York, Stony Brook, New York, USA

Address reprint requests to Dr Krukenkamp, Division of Cardiothoracic Surgery, University Hospital at Stony Brook, T19-080 Health Sciences Center, Stony Brook, NY 11794-8191
e-mail: ibkmd{at}hotmail.com

Presented at the Poster Session of the Thirty-Fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.

Background. Preconditioning protects the heart from ischemic injury, but some of its effects are reversed by ß-adrenergic blockade. We hypothesize that because nitric oxide is known to precondition the heart, the nitric oxide–generating ß-blocker nipradilol may simultaneously precondition and provide clinically relevant ß-blockade.

Methods. Isolated, crystalloid-perfused rabbit hearts underwent 1 hour of left anterior descending coronary artery ischemia followed by 1 hour of reperfusion. Before ischemia, six hearts received nipradilol, six received the nitric oxide donor L-arginine, four hearts received the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester before L-arginine, nine underwent ischemic preconditioning, and six received ß-blockade by esmolol before ischemic preconditioning. Seven hearts received no pretreatment (control). Action potential duration and ventricular pressure were measured. Infarct size was determined at the end of reperfusion.

Results. Both L-arginine and ischemic preconditioning prolonged action potential duration significantly at 60 minutes of reperfusion. Compared with control, infarct size was reduced by ischemic preconditioning (26% ± 4% versus 49% ± 3%, IPC versus control; p < 0.01), L-arginine (24% ± 2%; p < 0.01 versus control), and nipradilol (24% ± 2%; p < 0.01 versus control). Only nipradilol preserved peak developed pressure during reperfusion.

Conclusions. Despite its properties as a ß-adrenergic blocking agent, nipradilol was able to precondition the heart, probably as a result of its ability to produce nitric oxide.




This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. V. Cohen, X.-M. Yang, and J. M. Downey
Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies
Cardiovasc Res, May 1, 2006; 70(2): 231 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Qin, X.-M. Yang, L. Cui, S. D. Critz, M. V. Cohen, N. C. Browner, T. M. Lincoln, and J. M. Downey
Exogenous NO triggers preconditioning via a cGMP- and mitoKATP-dependent mechanism
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H712 - H718.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub
Anaesthetics and cardiac preconditioning. Part II. Clinical implications
Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Mieno, H. Horimoto, F. Watanabe, Y. Nakai, E. Furuya, and S. Sasaki
Potent adenylate cyclase agonist forskolin restores myoprotective effects of ischemic preconditioning in rat hearts after myocardial infarction
Ann. Thorac. Surg., October 1, 2002; 74(4): 1213 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. E. Saltman, T. O. Aksehirli, V. Valiunas, G. R. Gaudette, N. Matsuyama, P. Brink, and I. B. Krukenkamp
Gap junction uncoupling protects the heart against ischemia
J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 371 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Suematsu, T. Ohtsuka, H. Horimoto, K. Maeda, Y. Nakai, S. Mieno, and S. Takamoto
Long-term treatment with nipradilol, a nitric oxide-releasing {beta}-adrenergic blocker, enhances postischemic recovery and limits infarct size
Ann. Thorac. Surg., January 1, 2002; 73(1): 173 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Zaugg, M. C. Schaub, T. Pasch, and D. R. Spahn
Modulation of {beta}-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action
Br. J. Anaesth., January 1, 2002; 88(1): 101 - 123.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.